Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer

British Journal of Cancer

Volumn 91, Issue 8, 2004, Pages 1472-1476

  Birtle, A J ^a   Newby, J C ^a   Harland, S J ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

Combination chemotherapy; ECarboF; Prostate cancer

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; GONADORELIN; HYDROCORTISONE; STEROID; WARFARIN; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PREVENTION; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HEART LEFT VENTRICLE FAILURE; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; REMISSION; SEPSIS; SUBDURAL HEMATOMA; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME; ADENOCARCINOMA; BONE TUMOR; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; SOFT TISSUE TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; EPIRUBICIN; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE;

EID: 7944223145     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602177     Document Type: Article

References (21)

1. Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28: 8-15
2. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168: 2439-2443
3. Bonnefoi H, Smith IE, O'Brien ME, Seymour MT, Powles TJ, Allum WH, Ebbs S, Baum M (1996) Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin in patients with metastatic/locally advanced breast cancer. Br J Cancer 73: 391-396
4. Brausi M, Jones WG, Fossa SD, de Mulder PH, Droz JP, Lentz MA, Van Glabbeke M, Pawinski A (1995) High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer 31A: 1622-1626
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999a) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467
6. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999b) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467
7. Chao D, von Schlippe M, Harland SJ (1997) A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. Eur J Cancer 33: 1230-1233
8. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, Depauw M (1993) Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42: 119-129
9. Figg WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, Reed E, Sartor O (1996) Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14: 513-517
10. Fossa SD, Dearnaley DP, Law M, Gad J, Newling DW, Tveter K (1992) Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol 3: 361-366
11. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19: 62-71
12. Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA (1998) The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 41: 267-272
13. Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ (2001) Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 19: 3025-3028
14. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615
15. Newby JC, Leonard P, Fenwick E, Harland SJ (1999) Phase II study of epirubicin, carboplatin and infusional 5-FU in hormone resistant prostate cancer. BCRM Meeting. (Abstract)
16. Petrylak DP (2002) Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 20: 31-35
17. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20(8): 1996-2004
18. Smith DC, Dunn RL, Strawderman MS, Pienta KJ (1998) Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843
19. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756-1764
20. Ventafridda V, Saita L, Ripamonti C, De Conno F (1985) WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 7: 93-96
21. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, Benson M, Sawczuk I, Katz A, Olsson CA, Bagiella E, Pfaff C, Newhouse JH, Petrylak DP (2000) Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 163: 834-837